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Abstract
Powerful array-based single-nucleotide polymorphism–typing platforms have recently heralded a new era in
which genome-wide studies are conducted with increasing frequency. A genetic polymorphism associated with
population pharmacokinetics (PK) is typically analyzed using nonlinear mixed-effect models (NLMM). Applying
NLMM to large-scale data, such as those generated by genome-wide studies, raises several issues related to
the assumption of random effects, as follows: (i) Computation time: it takes a long time to compute the marginal
likelihood. (ii) Convergence of iterative calculation: an adaptive Gauss–Hermite quadrature is generally used to
estimate NLMM; however, iterative calculations may not converge in complex models. (iii) Random-effects mis-
specification leads to slightly inflated type-I error rates. As an alternative effective approach to resolving these
issues, in this article we propose a generalized estimating equation (GEE) approach for analyzing population PK
data. In general, GEE analysis does not account for inter-individual variability in PK parameters; therefore, the
usual GEE estimators cannot be interpreted straightforwardly, and their validities have not been justified. Here,
we propose valid inference methods for using GEE even under conditions of inter-individual variability, and pro-
vide theoretical justifications of the proposed GEE estimators for population PK data. In numerical evaluations
by simulations, the proposed GEE approach exhibited high computational speed and stability relative to the
NLMM approach. Furthermore, the NLMM analysis was sensitive to the misspecification of the random-effects
distribution, and the proposed GEE inference is valid for any distributional form. An illustration is provided using
data from a genome-wide pharmacogenomic study of an anticancer drug.
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1. Introduction
Individual variations in drug efficacy and side effects pose serious problems in medicine. These variations
are influenced by factors such as drug-metabolizing enzymes, drug transporters, and drug targets (e.g.,
receptors). For manymedications, these factors can be attributed to genetic polymorphisms [1, 2]. Indeed,
these genomic biomarkers are sometimes used to improve drug responses and reduce side effects by
controlling the medication or dose according to the patient’s genotype [3, 4].
However, only a few of these genomic biomarkers have been validated. For this reason, many phar-
macogenomics (PGx) studies have been launched around the world. The purpose of these studies is to
identify genes that affect drug-metabolizing enzymes, drug transporters, and drug targets. Therefore,
pharmacokinetics (PK) studies that include analyses of single-nucleotide polymorphisms (SNPs) as ge-
nomic markers in candidate-gene or genome-wide studies can be used to identify these genes. The avail-
ability of powerful array-based SNP-typing platforms has facilitated genome-wide studies, which have
become a standard strategy. Such platforms make available to researchers genotype data for 100,000–
4,300,000 SNPs.
In PK studies, it is common to apply compartmental models, which are often nonlinear models that in-
clude several PK parameters, in order to describe the profiles of drug concentrations in blood [5]. Because
drug concentrations in blood are usually related to drug efficacy and side effects, via their interactions
with drug-metabolizing enzymes, drug transporters, and drug targets, differences in PK parameters indi-
cate differences in effectiveness and toxicity. Therefore, one object of PGx studies is to identify genes
associated with PK parameters.
Because drug-concentration data is measured from multiple subjects in PGx studies, inter-individual
variability in PK parameters should be considered. Such data is referred to as population PK data. If
the impact of inter-individual variability in model parameters is ignored, no statistically valid inference
is possible. The mixed-effects model, which includes both fixed and random effects, is one method that
accounts for inter-individual variability. Inter-individual variability in model parameters is modeled as
random effects with strong parametric assumptions about the random-effects distribution. These mod-
els have often been used in analysis of longitudinal data [6], and they represent a useful method for
accounting for inter-individual variability. Moreover, the nonlinear mixed-effects model (NLMM), an
extension of the mixed-effects model to nonlinear functions, is often used to analyze population PK data
[7, 8, 9, 10, 11].
The association between PK parameters and SNPs are typically analyzed using an NLMM [12, 13,
14, 15] in conjunction with population PK data. However, applying an NLMM to large-scale data can be
problematic for the following reasons:
(i) Computation time: NLMMs can be computationally intensive, because these models must compute
the marginal log-likelihood by integrating out random effects [8]. In NLMMs, inferences about
model parameters are based on the marginal log-likelihood function, which includes a multiple
integral with respect to the unobservable random effects. Because the regression functions are non-
linear, the integral in the marginal log-likelihood function has no closed form, and it is necessary
to compute the integral. To address this issue, various methods have been proposed to compute the
integral approximation. However, these methods are computationally inefficient.
(ii) Convergence of iterative calculations: For instance, a major statistical software package, the SAS
NLMIXED Procedure (SAS Institute, Inc., Cary, North Carolina) with adaptive Gauss–Hermite
quadrature, is now used to approximate the maximum marginal log-likelihood [16, 17]. These
computations are based on iterative calculations; for complex models, however, these calculations
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may not converge [18, 19]. If iterative calculations do not converge, we derive no information from
valuable data.
(iii) Random-effects misspecification: Random-effects misspecification leads to bias in parameter esti-
mates of the regression coefficients, and slightly inflates type-I error rates of tests for the regression
coefficients in generalized mixed-effects models [20, 21, 22, 23] and NLMMs [18]. Therefore,
careful model building and checking are needed for each of the 100,000–4,300,000 analyses, but
in practice this may be difficult to apply.
In conclusion, it seems that these three problems occur in association with a strong assumption of random
effects.
Therefore, we consider a new method that uses a potentially misspecified model to avoid the strong
assumptions of the random-effects distribution. Misspecified models are useful and powerful tools for
studying the behavior of estimators under model misspecification. Model misspecification means that an
incorrect working model is used for estimation. In this paper, we consider a “true” model that includes
inter-individual variability in model parameters as fixed-effect parameter vectors βi for each subject i
(= 1, 2, . . . , K), and a “working” model that misspecifies the presence of inter-individual variability in
model parameters as a common parameter vector β. In this paper, we describe a new interpretation of the
estimator β̂ as a weighted average of the individual parameter vectors βi. The proposed method allows
for computation that is faster than NLMM by a factor of 100, performs stable computations, and is robust
for various structures of individual variations, because it is based on misspecified fixed-effect models
instead of random-effect models.
A general theory of misspecified models has been proposed by White [24] for maximum-likelihood
methods, and by Yi and Reid [25] for estimating equations. In both papers, the authors demonstrate the
asymptotic normality of estimators of working-model parameters under mild conditions. The method
we propose uses generalized estimating equations (GEE) of a working model based on Yi and Reid’s
result. GEE has been widely used in regression analyses of the generalized linear models with correlated
response, such as repeated-measurement data [26, 27, 28]. Under mild conditions, the estimator from
GEE of a misspecified model is consistent and asymptotically normal. Therefore, the proposed method
may be applied to correlated-response data with inter-individual variability in model parameters, which
includes a wide range of applications. In this paper, however, we focus on the problem of estimating PK
parameters in the presence of inter-individual variability in PGx studies, i.e., the motivating example.
The proposed method focuses only on estimating fixed effect parameter vectors, because one object
of PGx studies is to identify genes associated with PK parameters. Other parameters are nuisance pa-
rameters. Therefore, a misspecified model that gives an estimator for a weighted average of fixed effect
parameter vectors is “intentionally” used. As a result, the proposed estimator βˆ is different from the
estimator of NLMMs. Marginal (or population-averaged) models and mixed (or subject-specific) models
can lead to a different estimator in non-linear settings [29]. The proposed method relates to marginal
models.
For each SNP, there are three genotypes for each locus: the “aa”, “Aa”, and “AA” genotypes, where
“a” is the major allele and “A” is the minor allele. There are often a considerable number of genes for
which the frequency of the minor homozygous genotype, “AA”, is very small, because a SNP is defined
as a mutation involving a single DNA base substitution that is observed with a frequency of at least 1% in
a population. Therefore, for valid statistical inference, a small–sample correction is needed. To address
the small–sample size problem, we propose a Wald-type test and an asymptotic F -test for determining
the effects of a genetic polymorphism on PK parameters (see Section 3.5).
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In Section 2, motivating data and issues of NLMM are introduced. In Section 3, misspecified models
and the proposed method are presented, and some of the proposed method’s theoretical properties are
discussed. In Section 4, we study the performance of the proposed method using simulations. In Section
5, we present the application of the method to published experimental data. We present our concluding
remarks in Section 6.
2. Motivating example
The motivation for this paper stems from an PGx study data [30] on gemcitabine (2’,2’-difluorodeoxy-
cytidine), which is a nucleoside anticancer drug. The study was designed to screen for genes related to
the PK of gemcitabine. The participants consisted of 233 gemcitabine-naive cancer patients (mainly with
pancreatic carcinoma). For the PK analysis, heparinized blood samples were taken before administration
and at 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, and 4.5 hours after the beginning of the administration. The dose was
adjusted according to the surface area of the body of each subject. A total of 109,365 gene-centric SNPs
were genotyped using the Sentrix Human-1 Genotyping BeadChip (Illumina Inc., San Diego, CA).
Because the main object of this PGx study was to screen PK-related genes, the SNP genotype effect
on PK parameters was modeled using a compartmental model. Compartmental models, which are derived
from differential equations that describe drug kinetics, are nonlinear models with several PK parameters.
It is common to apply such models in order to describe the profiles of drug concentrations in blood.
In general, analyses of genome-wide data use appropriate statistical methods to investigate the asso-
ciation between an outcome variable and a set of SNPs [31]. Based on the results, favorable SNPs that
strongly associate with the outcome variable are screened with appropriate criteria (e.g., the Bonferroni
adjustment, false-discovery rate, etc.). The appropriate statistical methods are determined by the nature
of the outcome variable and the study design (e.g., trend tests for odds ratios are used in case-control
studies), and these analyses are commonly performed one by one for each SNP. In genome-wide PGx
studies, to identify genes that associate with PK parameters, analyses of the associations between PK
parameters and SNPs are applied to population PK data. We consider that the SNP genotype effect re-
flects the difference in average PK parameters between different genotypes. Moreover, because the PK
data include multiple individuals, the data are population PK data, and we must consider the impact of
inter-individual variability in PK parameters.
Now, we introduce notations and describe the data structure. Suppose we have a plasma drug concen-
tration dataset withK subjects and a genotype dataset withM SNPs. For each subject i (= 1, 2, . . . , K),
there is a random (ni× 1)-dimensional vectorYi = (Yi1, Yi2, . . . , Yini)T, a covariate (q× p)-dimensional
matrixX
(m)
i , and an (ni × 1)-dimensional vector ti = (ti1, ti2, . . . , tini)T representing time after starting
measurement. The covariate matrix X
(m)
i includes genotype data of the m-th SNP (m = 1, 2, . . . ,M).
Because similar analysis is repeated for each of the M SNPs, we shall write Xi instead of X
(m)
i for
simplicity. Note that the superscript “T” indicates the transpose of a matrix or a vector.
In the literature to date, several studies have analyzed a genetic polymorphism in relation to popula-
tion PK data using NLMMs [12, 13, 14, 15]. In NLMMs, it is often assumed that Yi arises from the
non-linear model,
Yi = f(θi, ti) + ǫi,
θi = Xiβ + Ziγ i,
ǫi ∼ N(0,Ri),
where f is a compartmental model function that is non-linear in its PK parameters θi, ǫi is a error vector,
β and γi are vectors of fixed effects and random effects, Zi is a design matrix for random effects, andRi
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Figure 1. A fitted two-compartment constant intravenous infusion model. K0 is the infusion rate
constant,Dose is the amount of drug administered, Tin is the infusion time,K12 and K21 are
inter-compartmental transfer rate constants connecting the central and peripheral compartments, Vd is
the volume of the central compartment, and Kel is the first order elimination rate constant.
is a covariance matrix. The γi are assumed to have a multivariate normal distribution with mean vector 0
and a covariance matrixG. NLMM incorporates unmeasured random effects γi into the compartmental
model function to account for inter-individual variability in the PK parameters θi.
Because two-compartment models have been widely used in gemcitabine PK analyses [32, 33], we
fitted a two-compartment constant intravenous-infusion model (Figure 1). For the gemcitabine PGx data,
the function form of f is as follows:
f(θi, tij) =

K
(i)
0 (K
(i)
21 −a
(i))
V
(i)
d
a(i)(a(i)−b(i))
{exp(−a(i)tij)− 1}+
K
(i)
0 (b
(i)−K
(i)
21 )
V
(i)
d
b(i)(a(i)−b(i))
{exp(−b(i)tij)− 1}
tij ≤ T (i)in
K
(i)
0 (K
(i)
21 −a
(i)){exp(−a(i)T
(i)
in
)−1}
V
(i)
d
a(i)(a(i)−b(i))
exp{−a(i)(tij − T (i)in )}+
K
(i)
0 (b
(i)−K
(i)
21 ){exp(−b
(i)T
(i)
in
)−1}
V
(i)
d
b(i)(a(i)−b(i))
exp{−b(i)(tij − T (i)in )}
tij > T
(i)
in
(1)
where
K
(i)
0 = Dose
(i)/T
(i)
in ,
a(i) = {(K(i)el +K(i)12 +K(i)21 ) +
√
(K
(i)
el +K
(i)
12 +K
(i)
21 )
2 − 4K(i)el K(i)21 )}/2,
b(i) = {(K(i)el +K(i)12 +K(i)21 )−
√
(K
(i)
el +K
(i)
12 +K
(i)
21 )
2 − 4K(i)el K(i)21 )}/2,
and
θi =
(
log V
(i)
d , logK
(i)
el , logK
(i)
12 , logK
(i)
21
)T
,
because the PK parameters are restricted to be positive, and in practice are empirically log-transformed
[34]. Commonly, the three genotypes are considered in evaluating the relationship between SNPs and
the PK parameters. We use the dummy variables xiAa and xiAA for the covariate matrix Xi. Let
(xiAa, xiAA) = (0, 0), (1, 0), or (0, 1) denote that the i-th subject has the genotype “aa”, “Aa”, or “AA”,
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respectively. We assume that the effect of a SNP on the PK parameter can be described by the following
relationship;
θi =

βVd + βVdAaxiAa + βVdAAxiAA + γiVd
βKel + βKelAaxiAa + βKelAAxiAA + γiKel
βK12 + βK12AaxiAa + βK12AAxiAA + γiK12
βK21 + βK21AaxiAa + βK21AAxiAA + γiK21
 ,
where (βVd, βKel, βK12, βK21) is an intercept parameter for each PK parameter, and (βVdAa , βKelAa , βK12Aa ,
βK21Aa) and (βVdAA , βKelAA, βK12AA, βK21AA) are the effect parameters of a SNP genotype “Aa” and “AA”
for each PK parameter, respectively.
In order to evaluate the effect parameters of a SNP genotype, a test for the effect for the single
genotype (e.g., H0 : βVdAa = 0 vs. H1 : βVdAa 6= 0) and a multiple degrees-of-freedom test (e.g.,
H0 : βVdAa = βVdAA = 0 vs. H1 : not H0) can be considered. When the null hypotheses, H0, of these
tests are rejected at an appropriate significance level, it can be concluded that the SNP affects the profiles
of drug concentrations in blood.
However, applying an NLMM to large-scale data, such as genome-wide PGx studies, can be prob-
lematic. (i) NLMMs can be computationally intensive, because these models must compute the marginal
log-likelihood by integrating out random effects [8]. (ii) These computations are based on iterative cal-
culations, and may not converge in complex models [18, 19]. (iii) Random-effects misspecification leads
to bias in parameter estimates of the regression coefficients and slightly inflates type-I error rates of tests
for the regression coefficients in an NLMM [18].
Therefore, we consider an alternative approach that relates to a marginal modeling approach that
avoids the specification of random effects. The approach potentially results in misspecification of the
model for the parameters of interest. Therefore, we evaluated the estimator based on the proposed ap-
proach via a misspecified model.
3. Estimation and inference
3.1 Misspecified models
Misspecified models are useful and powerful tools for studying a behavior of estimators under model mis-
specification. Model misspecification means that an incorrect working model is used for estimation. The
proposed method “intentionally” uses an incorrect working model that gives an estimator for a weighted
average of fixed effect parameter vectors.
The general theory of misspecified models has been proposed by White [24] for maximum likelihood
methods, and by Yi and Reid [25] for estimating equations. White showed that the maximum likelihood
estimator β̂ of a misspecified model converges to a constant vector β∗ which minimizes the Kullback–
Leibler divergence. A similar property holds in the case of estimating equations. Under mild conditions,
Yi and Reid showed that
√
K(β̂ − β∗) is asymptotically normally distributed with a mean vector 0 and
a covariance matrixVs that can be consistently estimated by the so-called sandwich estimator. However,
because β∗ generally do not have a simple analytical form, we need to evaluate the properties of β∗.
The literature includes several attempts to uncover the relation between the parameters of a true
model and the estimators of model parameters from an incorrect working model. For example, misspeci-
fied models under non-proportional hazards models with a time-varying effect parameter β(t) have been
discussed in semi-parametric survival models [35, 36]. Xu and O’Quigley [35] evaluate an asymptotic
property of the estimator from a misspecified proportional-hazards model that replaces β(t) with a con-
stant β. They showed that the estimator β̂ converges in probability to a constant β∗ that is approximated
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by a weighted average of β(t) over time, β∗ ≈
∫∞
0
β(t)v(t)dF (t)/
∫∞
0
v(t)dF (t), where v(t) is the con-
ditional variance of a stochastic process Z(t), and Z(t) is a possibly time-dependent covariate. Xu and
O’Quigley showed that the estimator β̂ can be interpreted as a weighted average of true parameters even
when an incorrect working model is used.
In this paper, we consider GEE of a misspecified model. We assume a true model with inter-individual
variability in model parameters as fixed-effect parameter vectors βi, and a working model that misspec-
ifies the presence of inter-individual variability in model parameters as a common parameter vector β.
We demonstrate a new interpretation of the estimator β̂ as a weighted average of the individual parameter
vectors βi.
3.2 Assumptions about the true model
To describe the true structure of the observations, we assume that the true cumulative distribution of Yi
is G(Yi;βi, φ, ξ) with density g(Yi;βi, φ, ξ), where βi = (βi1, βi2, . . . , βip)
T is a (p × 1)-dimensional
vector of effect parameters with inter-individual variability as fixed effects, φ is a scale parameter, and ξ
is a variance model parameter vector.
The expectation of the observation is modeled as E[Yij ] =
∫
YijdG(Yi;βi, φ, ξ) = f(Xi, tij;βi),
where f is a PK function that is nonlinear in its PK parameters θi, θi = (θi1, θi2, . . . , θiq)
T is an individual
PK parameter (q × 1)-dimensional vector, and θi is modeled in linear form as θi = Xiβi.
Furthermore, we assume that the variance is modeled as Var[Yij] = φv(Xi, tij;βi, ξ), where v is a
known variance function that has the variance model parameter vector ξ.
3.3 An estimator of a weighted average effect by GEE
Under the true distribution in Section 3.2, an average effect may be obtained heuristically by replacing
βi with a constant β and then fitting to data. We consider GEE of a working model that has parameters
β. GEE is well known to be inadequate when the mean structure is misspecified. However, we will show
that the estimator β̂ can be interpreted as a weighted average effect under the true model, in Section 3.4.
We define GEE of a potentially misspecified model as
U(β) =
K∑
i=1
Ui(Yi;β) =
K∑
i=1
DTi V
−1
i Si = 0, (2)
where
Di =
∂µi
∂βT
=
(
∂µi
∂β1
,
∂µi
∂β2
, . . . ,
∂µi
∂βp
)
,
µi = f(Xi, ti;β),
Vi = φA
1/2
i Ri(α)A
1/2
i ,
Ai = diag(v(Xi, ti1;β, ξ), v(Xi, ti2;β, ξ), . . . , v(Xi, tini;β, ξ)),
Si = Yi − µi,
Ri(α) is a working correlation (ni × ni)-dimensional matrix that can depend on a parameter vector α,
and β = (β1, β2, . . . , βp)
T is a parameter (p×1)-dimensional vector that is common between individuals.
The true distribution has the effect parameter vector βi, which has inter-individual variability; however,
this working model assumes no inter-individual variability. In equation (2), the individual PK parameter
(q×1)-dimensional vectorψi = (ψi1, ψi2, . . . , ψiq)T is modeled asψi = Xiβ. Note that diag() indicates
a diagonal matrix with diagonal elements in parentheses.
Here, we denote the solution to equation (2) as β̂. Yi and Reid [25] showed following theorems.
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Theorem 1. Under the true model (the distribution function of Yi is G), the estimator β̂ converges in
probability to a constant vector β∗ as K → ∞, where β∗ is a constant vector that satisfies the
equation
E[Ui(Yi;β∗)] =
∫
Ui(Yi;β∗)dG(Yi;βi, φ, ξ) = 0. (3)
Theorem 2. Under the true model,
√
K(β̂ − β∗) is asymptotically normal with a mean vector 0 and a
covariance matrixVs as K →∞, where
Vs = lim
K→∞
KI0(β∗)
−1I1(β∗)I0(β∗)
−1
is a sandwich variance,
I0(β) = E
[
∂
∂β
{U(β)}T
]
=
K∑
i=1
DTi V
−1
i Di,
and
I1(β) = E
[{U(β)}{U(β)}T] = K∑
i=1
DTi V
−1
i Cov[Yi]V
−1
i Di.
3.4 Interpretation
The solution β∗ to equation (3) can be interpreted as a weighted average of the individual parameter
vectors βi. In equation (3) from Theorem 1, β∗ minimizes the distance between the true model and the
misspecified model. For example, when Ui is the score function, White [24] showed that β∗ minimizes
the Kullback–Leibler divergence between the true model and the misspecified model.
However, β∗ do not have a simple analytical form. To evaluate the properties of β∗, we consider a
first-order Taylor expansion of the expectation of equation (2) around β∗ = βi. As a result, we get
β∗ ≈
{
K∑
i=1
I0i(βi)
}−1{ K∑
i=1
I0i(βi)βi
}
(4)
which is a weighted average of the individual parameter vectors βi with weights I0i(βi), where I0i(βi) =
E[∂Ui(Yi;β∗)/∂β
T
∗ |β∗=βi ] is an inverse matrix of the model-based variance of the i-th subject. The
derivation of equation (4) is shown in Appendix A.
Therefore, according to Theorem 1 and equation (4), the estimator β̂ from the working model can
asymptotically estimate a weighted average of the individual parameter vectors βi. For instance, if βi =
β + γi, then β∗ ≈ β +
{∑K
i=1 I0i(βi)
}−1 {∑K
i=1 I0i(βi)γi
}
; moreover, if βi = β + γi and γ i = 0,
then β∗ = β. The model corresponding to (2) is a misspecified model. Nevertheless, the estimator β̂
converges to β∗ and can be interpreted as population-weighted average parameters. Furthermore, this
approach is robust for various structures of inter-individual variability (see Section 4.1), because it does
not require a strong assumption of a random-effect distribution.
3.5 A Wald-type test and an asymptotic F -test
As indicated in Section 1, a small–sample correction is needed for valid statistical inference in genome-
wide PGx studies that analyze SNP genotyping data. Therefore, we consider a Wald-type test based on t
distributions and an asymptotic F -test instead of the asymptotic Wald chi-square tests.
An efficient and robust method for analyzing population pharmacokinetic data — 9/26
We considered linear hypotheses of the form H0 : c
Tβ = 0 versus H1 : c
Tβ 6= 0 , where c =
(c1, c2, . . . , cp)
T is a contrast-coefficient (p× 1)-dimensional vector.
We proposed a Wald-type test statistic;
W =
√
KcTβ̂√
cTV̂sc
=
√
KcTβ̂/
√
cTVsc√
d(cTV̂sc/cTVsc)/d
,
where
V̂s = K Î0(β̂)
−1Î1(β̂)̂I0(β̂)
−1 (5)
is the estimator of the covariance matrixVs,
Î0(β̂) =
K∑
i=1
D̂Ti V̂
−1
i D̂i,
Î1(β̂) =
K∑
i=1
D̂Ti V̂
−1
i Ĉov[Yi]V̂
−1
i D̂i =
K∑
i=1
D̂Ti V̂
−1
i ŜiŜ
T
i V̂
−1
i D̂i,
D̂i =
∂µi
∂βT
∣∣∣∣
β=β̂
µ̂i = f(Xi, ti; β̂),
V̂i = φ̂Â
1/2
i R̂i(α̂)Â
1/2
i ,
Âi = diag(v(Xi, ti1; β̂, ξ̂), v(Xi, ti2; β̂, ξ̂), . . . , v(Xi, tini; β̂, ξ̂)),
and
Ŝi = yi − µ̂i.
Because
√
KcTβ̂/
√
cTVsc is asymptotically normally distributed with mean 0 and variance 1 under
the null hypothesis, and assuming that d(cTV̂sc/c
TVsc) follows a chi-square distribution with d degrees
of freedom (d.f.), the test statisticW is asymptotically t-distributed with d d.f., which must be estimated.
We applied the moment estimator of the d.f. d̂ = {trace(Ψ̂M)}2/trace(Ψ̂MΨ̂M), as proposed by
Fay and Graubard [37], where Ψ̂ = block-diag(Ψ̂1, Ψ̂2, . . . , Ψ̂K) is a block-diagonal matrix, Ψ̂i =
D̂Ti V̂
−1
i ŜiŜ
T
i V̂
−1
i D̂i, Mi = D̂
T
i V̂
−1
i D̂icc
TD̂iV̂
−1
i D̂
T
i , and M = block-diag(M1,M2, . . . ,MK) is a
block-diagonal matrix. We discuss a derivation of d̂ in Appendix B.
We also considered approximating the distribution of multiple degrees-of-freedom tests of H0 :
CTβ = 0 versusH1 : C
Tβ 6= 0, whereC = (c1, c2, . . . , cL) is a contrast-coefficient (p×L)-dimensional
matrix and L is the number of contrast-coefficient vectors that one wishes to test.
We proposed an asymptotic F -test statistic:
F =
1
L
{
(CTβ̂)T(CTV̂sC)
−1(CTβ̂)
}
.
The statistic F is asymptotically F -distributed with a numerator d.f. L and a denominator d.f. ν that must
be estimated. We applied the moment estimator of the denominator d.f.,
ν̂ =
2
(∑L
l=1
d̂l
d̂l−2
)
(∑L
l=1
d̂l
d̂l−2
)
− L
,
as proposed by Fai and Cornelius [38] (see also [39]), where d̂l is the estimator of the d.f. of theWald-type
test statistic for the l-th contrast-coefficient vector.
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3.6 Bias correction for V̂s
The sandwich-variance estimator V̂s is biased downward under small–sample size conditions, as shown
by Mancl and DeRouen [40] (see also [41, 42, 43]). As indicated in Section 1, a bias correction is also
needed in genome-wide PGx studies.
To calculate V̂s, a product of the residual vector ŜiŜ
T
i is used to estimate Cov[Yi]. However, using a
first-order Taylor expansion ofU(β̂) = 0 and Ŝi around β̂ = β∗, β̂ − β∗ ≈ I0(β∗)−1
∑K
i=1D
T
i∗V
−1
i∗ Si∗
and Ŝi ≈ Si∗ − DTi∗(β̂ − β∗), we have E[ŜiŜTi ] ≈ (Ini − Hi)Cov[Yi](Ini − Hi)T 6= Cov[Yi],
where Di∗, Vi∗, and Si∗ can be obtained by replacing β by β∗ in the expression Di, Vi, and Si;
Hi = Di∗I0(β∗)
−1DTi∗V
−1
i∗ ; and Ini is an (ni×ni)-dimensional identity matrix. Replacing Ŝi in equation
(5) by S˜i = (Ini −Hi)−1Ŝi gives the bias-corrected sandwich-variance estimator,
V˜s = K Î0(β̂)
−1I˜1(β̂)̂I0(β̂)
−1, (6)
where
I˜1(β̂) =
K∑
i=1
D̂Ti V̂
−1
i S˜iS˜
T
i V̂
−1
i D̂i,
and Ĥi = D̂iÎ0(β̂)
−1D̂Ti V̂
−1
i is the leverage of the i-th subject [40, 44]. Moreover, an estimator of the
d.f. d˜ and ν˜ are given in a similar way;
d˜ = {trace(Ψ˜M˜)}2/trace(Ψ˜M˜Ψ˜M˜)
and
ν˜ =
{
2
(
L∑
l=1
d˜l
d˜l − 2
)}
/
{(
L∑
l=1
d˜l
d˜l − 2
)
− L
}
,
where
Ψ˜ = block-diag(Ψ˜1, Ψ˜2, . . . , Ψ˜K),
Ψ˜i = D̂
T
i V̂
−1
i S˜iS˜
T
i V̂
−1
i D̂i,
M˜ = block-diag(M˜1, M˜2, . . . , M˜K),
and
M˜i = (Ini − Ĥi)−1D̂Ti V̂−1i D̂iccTD̂iV̂−1i D̂Ti (Ini − Ĥi)−T.
3.7 Example application: Compartment models and the effects of SNPs
In this study, we applied our methods to a genome-wide PGx study [30], introduced above in Section 2.
We introduce the true distribution of Yi and a generalized estimating equation for the data. It is
common to use a constant coefficient of variation (CV) model in PK data analysis [9, 45, 46, 47]. Under
the constant CV model, the expectation and variance of the log-transformed random vector,Y∗i = logYi,
is modeled as E[Y ∗ij ] = f
∗(Xi, tij ;βi), Var[Y
∗
ij ] = σ
2, and v(Xi, tij;βi, ξ) = 1, where
f ∗(Xi, ti;βi) = log f(Xi, ti;βi) (7)
is the log-transformed PK function, and f(Xi, ti;βi) is given by equation (1). Furthermore, the working
correlation matrix is modeled as, Ri(α) = Ini .
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Along with NLMM as shown in Section 2, in order to evaluate the association between PK parameters
and SNPs, the individual PK parameters in GEE of a working model is modeled as
ψi =

log V
(i)
d
logK
(i)
el
logK
(i)
12
logK
(i)
21
 = Xiβ =

βVd + βVdAaxiAa + βVdAAxiAA
βKel + βKelAaxiAa + βKelAAxiAA
βK12 + βK12AaxiAa + βK12AAxiAA
βK21 + βK21AaxiAa + βK21AAxiAA
 ,
where the covariate matrix is
Xi =

1 xiAa xiAA 0 0 0 0 0 0 0 0 0
0 0 0 1 xiAa xiAA 0 0 0 0 0 0
0 0 0 0 0 0 1 xiAa xiAA 0 0 0
0 0 0 0 0 0 0 0 0 1 xiAa xiAA
 , (8)
and the parameter vector is
β = (βVd , βVdAa, βVdAA, βKel, βKelAa, βKelAA, βK12, βK12Aa, βK12AA, βK21 , βK21Aa, βK21AA)
T.
4. Simulations
Simulations were conducted to study the performance of the proposed Wald-type test and asymptotic
F -test for population PK data. The simulation conditions for population PK data were determined by
reference to an actual genome-wide PGx study [30].
For simplicity, observed responses y∗i , which should have individual variations, were generated from
the NLMM as follows:
θi =

(βVd + γiVd) + βVdAaxiAa + βVdAAxiAA
βKel + βKelAaxiAa + βKelAAxiAA
(βK12 + γiK12) + βK12AaxiAa + βK12AAxiAA
(βK21 + γiK21) + βK21AaxiAa + βK21AAxiAA
 (9)
where γi = (γiVd, γiK12, γiK21)
T is a random-effect vector of the i-th subject for each PK parame-
ter, for which conditions are shown in Section 4.1 and Section 4.2. Further, we assumed Y∗i |γi ∼
N(f ∗(Xi, ti;βi), σ
2Ini), where f
∗ is a log-transformed two-compartment constant intravenous-infusion
PK function in equation (7) setting Dose(i) to 1400 mg and T
(i)
in to 0.5 hours. The intercept terms of the
log-transformed PK parameters were set to βVd = 3.72, βKel = 1.38, βK12 = −1.89, and βK21 = −0.35;
the standard deviation σ was set to 0.27; and values of the remaining parameters are shown in Section 4.1
and Section 4.2. Note that these parameters were set based on a preliminary NLMM analysis of gemc-
itabine data without covariates; we assumed that the random-effect vector γi is normally distributed with
a mean vector 0 and a diagonal covariance matrix diag(τ 2Vd , τ
2
K12
, τ 2K21), because the random effects of
the elimination parameter Kel were too small. In the simulations, we changed the blood sampling points
to 0.1, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, and 4.5 hours after drug administration. The covariate matrices Xi in
equation (8) were generated non-randomly by taking
(xiAa, xiAA) =

(0, 0) genotype aa
(1, 0) genotype Aa
(0, 1) genotype AA
.
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In actual studies, the sample size of each genotype group is not controlled, but depends on allele
frequency. Generally, these studies are likely to have unequal sample sizes for different genotypes and a
minor-allele frequency (MAF) of less than 0.5, most commonly around 0.2 [48]. When MAF is small,
there are too few subjects homozygous for the minor allele. Therefore, the MAF was set to 0.25 or 0.50.
If we let naa, nAa, and nAA denote the sample size of each genotype, then MAF = (nAa + 2nAA)/2n.
We assumed that the population was in Hardy–Weinberg equilibrium, with the total sample size n = 100;
the sample size for each group was set to naa = 56, nAa = 37, and nAA = 7 for MAF = 0.25, and
naa = 25, nAa = 50, and nAA = 25 for MAF = 0.50. The total sample size n = 100 is not realistic for
genome-wide PGx studies, but is sufficient to evaluate statistical performance.
For each data configuration, 1000 simulations were generated.
For each simulation, the generalized estimating equation of a misspecified model in equation (2) was
fitted assuming the two-compartment constant intravenous-infusion model as shown in Section 3.7, and
the NLMMwas fitted assuming a normal random-effects model with adaptive Gauss–Hermite quadrature.
We used a diagonal covariance matrix for the random-effect vector γi, which is normally distributed with
a mean vector 0, and a covariance matrix diag(τ 2Vd , τ
2
K12
, τ 2K21) for the NLMM, which is a commonly-used
method (see Section 2).
In order to assess the statistical performance of tests for the effect of a SNP on PK parameters (e.g.,
H0 : βVdAa = 0 vs. H1 : βVdAa 6= 0 and H0 : βVdAa = βVdAA = 0 vs. H1 : not H0), we applied
the proposed Wald-type test using V̂s in equation (5) (hereinafter referred to as GEE (V̂s)) and V˜s in
equation (6) (hereinafter referred to as GEE (V˜s)), and a Wald test in the NLMM for testing linear
hypotheses. In addition, we applied the proposed asymptotic F -test using V̂s in equation (5) and V˜s in
equation (6), and an asymptotic F -test in the NLMM for testing linear hypotheses. As we tested for the
effect of the SNP on the parameters Vd, Kel, K12, and K21 as a whole, we used L = 2,
CVd =
(
0 1 0 0 0 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0 0 0 0
)
,
CKel =
(
0 0 0 0 1 0 0 0 0 0 0 0
0 0 0 0 0 1 0 0 0 0 0 0
)
,
CK12 =
(
0 0 0 0 0 0 0 1 0 0 0 0
0 0 0 0 0 0 0 0 1 0 0 0
)
,
and
CK21 =
(
0 0 0 0 0 0 0 0 0 0 1 0
0 0 0 0 0 0 0 0 0 0 0 1
)
,
respectively. Note that the simulation data assume that the effect parameters of a SNP do not include
random effects (e.g., βVdAa∗ ≈ βVdAa) as shown in equation (9). The two-tailed significance level of all
tests was set to 0.05.
For each simulation, we evaluated the type-I error rates, powers, mean biases, mean-squared errors
(MSEs), computation times, and convergence proportions of the iterative calculations. Furthermore, we
implemented numerical computations for estimation and inference of GEE (V̂s) and GEE (V˜s) using the
SAS/NLMIXED Procedure (version 9.2, SAS Institute, Inc., Cary, North Carolina).
4.1 Type-I error rates
In this Section, we consider whether GEE (V̂s), GEE (V˜s), and NLMM can control type-I error rates
under random-effects misspecification in the following scenarios:
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Scenario 1 The random-effects distributions are “correctly specified” in NLMM. We assumed that the
random-effect vector γi is normally distributed with a mean vector 0 and a covariance matrix
diag(τ 2Vd, τ
2
K12
, τ 2K21), where the standard deviation of random effects was set to 0.12, 0.68, and
0.89 based on the preliminary analysis.
Scenario 2 The random-effects distributions are “misspecified” in NLMM. We assumed that each ele-
ment of the random-effect vector γi follows a uniform distribution;
γiVd ∼ Uniform(−
1
2
√
12τ 2Vd,
1
2
√
12τ 2Vd),
γiK12 ∼ Uniform(−
1
2
√
12τ 2K12,
1
2
√
12τ 2K12),
and
γiK21 ∼ Uniform(−
1
2
√
12τ 2K21,
1
2
√
12τ 2K21),
where the random-effect parameters τVd , τK12 , and τK21 are set to 0.12, 0.68, and 0.89, respectively.
Here, Var[γi•] = τ 2•.
Scenario 3 The random-effects distributions are “misspecified” in NLMM. We assumed that each
element of the random-effect vector γ i follows a gamma distribution; γiVd ∼ Gamma(τ 2Vd , 1),
γiK12 ∼ Gamma(τ 2K12 , 1), and γiK21 ∼ Gamma(τ 2K21 , 1), where the random-effect parameters τVd ,
τK12 , and τK21 are set to 0.12, 0.68, and 0.89, respectively. Here, Var[γi•] = τ 2•.
To evaluate type-I error rates, parameters of the SNP effect βVdAa, βVdAA, βKelAa, βKelAA, βK12Aa,
βK12AA, βK21Aa, and βK21AA are set to 0.0.
Type-I error rates, biases, and MSEs of GEE (V̂s), GEE (V˜s), and NLMM for MAF = 0.25 and 0.50
are shown in Tables 1 and 2. Because GEE (V̂s) and GEE (V˜s) differ only in variances, results of biases
and MSEs were combined as GEE (V̂s, V˜s) in Tables 1 and 2.
Type-I error rates for the proposed Wald-type test and asymptotic F -test of GEE (V̂s) and GEE
(V˜s) were well controlled below the nominal level of 5% for Scenarios 1–3 as shown in Tables 1 and 2.
However, the proposedWald-type test and asymptoticF -test of GEE (V˜s) were conservative. In addition,
type-I error rates for the proposed Wald-type test and asymptotic F -test of GEE (V̂s) were closer to the
nominal level than those of GEE (V˜s) despite the downward bias of V̂s (as shown in Section 3.6).
In contrast, except in Scenario 3 (MAF = 0.25, βK12), type-I error rates for the Wald-type test of
NLMM were inflated, as shown in Tables 1 and 2. To be more specific, for Scenario 1 (MAF = 0.25),
type-I error rates of NLMM were 0.067 (H0 : βK21Aa = 0); for Scenario 2 (MAF = 0.25), NLMM
values were 0.075 (H0 : βKelAa = 0), 0.078 (H0 : βK21Aa = 0), and 0.068 (H0 : βK21AA = 0); and for
Scenario 3, the NLMM value was 0.068 (H0 : βKelAa = 0). The results for MAF = 0.50 exhibit the same
tendencies. Because type-I error rates for Scenario 1 were closer to the nominal level than for Scenario
2, random-effects misspecification led to inflation of the type-I error rate in some instances. Furthermore,
except in Scenario 3 (MAF = 0.25, βK12), type-I error rates for the asymptotic F -test of NLMM were
inflated, as shown in Tables 1 and 2.
Except in Scenario 2 (MAF = 0.25) and Scenario 3, the biases did not differ greatly between GEE
(V̂s, V˜s) and NLMM, as shown in Tables 1 and 2. Therefore, the biases of GEE (V̂s, V˜s) might be
slightly larger than those of the NLMM.
The MSEs did not differ greatly between GEE (V̂s, V˜s) and NLMM, except in βK12AA, βK21Aa
and βK21AA, as shown in Tables 1 and 2. For βK12AA, MSEs of GEE (V̂s, V˜s) were larger than those of
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Table 1. Type-I errors, biases, and MSEs of GEE (V̂s), GEE (V˜s), and NLMM for MAF = 0.25 in
Scenarios 1–3.
Parameter βVdAa βVdAA βKelAa βKelAA βK12Aa βK12AA βK21Aa βK21AA
Type-I error rate
Scenario 1: “correctly specified” in NLMM
GEE (V̂s) 0.047 0.046 0.044 0.049 0.038 0.052 0.053 0.054
GEE (V˜s) Wald 0.047 0.043 0.043 0.041 0.037 0.048 0.050 0.050
NLMMa 0.058 0.051 0.061 0.040 0.050 0.056 c0.067 0.065
GEE (V̂s)
c0.030 0.041 0.039 c0.032
GEE (V˜s) F
c0.024 c0.033 c0.028 c0.019
NLMMa c0.074 c0.094 0.052 c0.077
Scenario 2: “misspecified” in NLMM (Uniform)
GEE (V̂s) 0.040 0.040 0.041 0.045 0.053 0.043 0.040 0.045
GEE (V˜s) Wald 0.038
c0.034 0.037 c0.034 0.049 c0.030 0.038 c0.027
NLMMa 0.058 0.064 c0.075 0.052 0.064 0.056 c0.078 c0.068
GEE (V̂s) 0.036 0.035 0.038 0.035
GEE (V˜s) F
c0.032 c0.026 c0.029 c0.021
NLMMa 0.061 c0.071 0.055 c0.086
Scenario 3: “misspecified” in NLMM (Gamma)
GEE (V̂s)
c0.025 0.042 c0.034 c0.033 0.042 0.054 0.048 0.037
GEE (V˜s) Wald
c0.023 0.039 c0.032 c0.019 0.041 0.041 0.041 c0.025
NLMMa 0.035 0.036 c0.068 0.059 c0.026 c0.033 0.062 0.057
GEE (V̂s) 0.037
c0.027 0.042 c0.034
GEE (V˜s) F
c0.031 c0.023 0.036 c0.026
NLMMa 0.043 0.062 c0.029 c0.068
Bias
Scenario 1: “correctly specified” in NLMM
GEE (V̂s, V˜s)
b −0.002 −0.002 <0.001 −0.001 0.012 0.008 −0.005 −0.055
NLMMa 0.003 0.001 <0.001 −0.004 0.011 −0.017 −0.005 −0.050
Scenario 2: “misspecified” in NLMM (Uniform)
GEE (V̂s, V˜s)
b −0.001 −0.006 <0.001 0.002 −0.004 d0.033 −0.007 d−0.039
NLMMa <0.001 0.003 −0.001 −0.001 −0.002 −0.005 0.003 0.001
Scenario 3: “misspecified” in NLMM (Gamma)
GEE (V̂s, V˜s)
b 0.001 −0.001 −0.001 0.002 −0.011 d−0.019 −0.004 −0.033
NLMMa −0.001 0.005 <0.001 −0.004 −0.002 0.005 −0.002 −0.028
MSE
Scenario 1: “correctly specified” in NLMM
GEE (V̂s, V˜s)
b 0.003 0.009 <0.001 0.002 0.033 d0.124 0.041 0.160
NLMMa 0.002 0.009 <0.001 0.002 0.027 0.097 0.047 0.166
Scenario 2: “misspecified” in NLMM (Uniform)
GEE (V̂s, V˜s)
b 0.002 0.009 <0.001 0.002 0.034 d0.121 0.033 0.132
NLMMa 0.003 0.009 <0.001 0.001 0.028 0.104 d0.046 d0.164
Scenario 3: “misspecified” in NLMM (Gamma)
GEE (V̂s, V˜s)
b 0.002 0.008 <0.001 0.002 0.031 d0.097 0.015 0.057
NLMMa 0.003 0.008 <0.001 0.002 0.021 0.071 0.018 0.062
aValues of the NLMM have been calculated from simulations with a low convergence proportion for iterative calculation (see Subsection 3.3).
bBecause GEE (V̂s) and GEE (V˜s) differ only in variances, results of biases were combined as GEE (V̂s, V˜s).
cValues that were ≤ 0.034 or ≥ 0.066 (binomial 99 % upper confidential limit, 0.05± 2.33
√
0.05(1 − 0.05)/1000) are highlighted.
dValues for which there was more than a 0.01 inferior difference between GEE (V̂s, V˜s) and the NLMM are highlighted.
The number of simulations was 1000.
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Table 2. Type-I errors, biases, and MSEs of GEE (V̂s), GEE (V˜s), and NLMM for MAF = 0.50 in
Scenarios 1–3.
Parameter βVdAa βVdAA βKelAa βKelAA βK12Aa βK12AA βK21Aa βK21AA
Type-I error rate
Scenario 1: “correctly specified” in NLMM
GEE (V̂s) 0.036 0.040 0.052 0.040 0.049 0.054 0.044 0.043
GEE (V˜s) Wald 0.035 0.038 0.051 0.036 0.047 0.052 0.044 0.037
NLMMa 0.044 0.051 0.054 0.061 c0.067 0.061 c0.073 0.058
GEE (V̂s) 0.061 0.047 0.052 0.038
GEE (V˜s) F 0.058 0.040 0.047
c0.030
NLMMa c0.072 c0.076 c0.080 c0.089
Scenario 2: “misspecified” in NLMM (Uniform)
GEE (V̂s) 0.037 0.038 0.046 0.038 0.037 0.041 0.030 0.034
GEE (V˜s) Wald 0.037 0.035 0.043 0.035 0.033 0.036 0.028 0.031
NLMMa 0.053 0.047 c0.080 c0.068 0.062 0.060 c0.077 c0.068
GEE (V̂s) 0.043 0.049 0.041 0.045
GEE (V˜s) F 0.040 0.046
c0.033 0.038
NLMMa 0.053 c0.081 c0.075 c0.074
Scenario 3: “misspecified” in NLMM (Gamma)
GEE (V̂s) 0.037
c0.028 0.050 0.037 0.038 0.047 0.040 0.040
GEE (V˜s) Wald 0.035
c0.027 0.046 c0.034 0.037 0.042 c0.033 c0.034
NLMMa 0.050 0.048 0.062 0.062 0.045 0.048 0.053 c0.066
GEE (V̂s) 0.035 0.056 0.045 0.053
GEE (V˜s) F
c0.032 0.051 0.043 0.046
NLMMa 0.052 c0.081 0.064 c0.083
Bias
Scenario 1: “correctly specified” in NLMM
GEE (V̂s, V˜s)
b <0.001 0.001< −0.001 −0.001 −0.007 0.008 0.007 −0.010
NLMMa −0.002 −0.003 0.001 0.001 0.002 0.012 −0.011 −0.008
Scenario 2: “misspecified” in NLMM (Uniform)
GEE (V̂s, V˜s)
b 0.002 0.002 <0.001 <0.001 −0.008 −0.011 0.002 −0.009
NLMMa 0.001 0.003 <0.001 −0.002 −0.001 −0.008 −0.002 −0.008
Scenario 3: “misspecified” in NLMM (Gamma)
GEE (V̂s, V˜s)
b 0.001 0.002 <0.001 −0.001 0.002 0.002 0.002 −0.004
NLMMa −0.001 0.002 <0.001 −0.001 0.011 d0.012 <0.001 −0.003
MSE
Scenario 1: “correctly specified” in NLMM
GEE (V̂s, V˜s)
b 0.003 0.004 0.001 0.001 0.046 0.053 0.058 0.071
NLMMa 0.003 0.004 <0.001 0.001 0.038 0.047 0.067 0.077
Scenario 2: “misspecified” in NLMM (Uniform)
GEE (V̂s, V˜s)
b 0.003 0.004 0.001 0.001 0.041 0.055 0.042 0.059
NLMMa 0.003 0.004 0.001 0.001 0.040 0.049 d0.062 d0.078
Scenario 3: “misspecified” in NLMM (Gamma)
GEE (V̂s, V˜s)
b 0.003 0.004 0.001 0.001 0.039 d0.055 0.019 0.027
NLMMa 0.003 0.004 0.001 0.001 0.030 0.042 0.024 0.033
aValues of the NLMM have been calculated from simulations with a low convergence proportion for iterative calculation (see Subsection 3.3).
bBecause GEE (V̂s) and GEE (V˜s) differ only in variances, results of biases were combined as GEE (V̂s, V˜s).
cValues that were ≤ 0.034 or ≥ 0.066 (binomial 99 % upper confidential limit, 0.05± 2.33
√
0.05(1 − 0.05)/1000) are highlighted.
dValues for which there was more than a 0.01 inferior difference between GEE (V̂s, V˜s) and the NLMM are highlighted.
The number of simulations was 1000.
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NLMM. For βK21Aa and βK21AA, MSEs of the NLMMwere larger than those of GEE (V̂s, V˜s). Therefore,
the MSEs of GEE (V̂s, V˜s) might not differ significantly from those of the NLMM.
In summary, the proposed Wald-type test and asymptotic F -test of GEE (V̂s) and GEE (V˜s) could
control type-I error rates in Scenarios 1–3, and the type-I error rates of the Wald-type test and asymptotic
F -test of the NLMM were inflated in some cases.
4.2 Powers
In this Section, we compare the powers of GEE (V̂s), GEE (V˜s), and NLMM in the four following
scenarios:
Scenario 4 The coefficients βVdAa and βVdAA were set to 0.05βVd , and the other effect parameters were
set to 0. In Scenario 4, βVdAa = 0.05βVd implies that log V
(i)
d of the population with SNP genotype
“Aa” increases by 5% compared with the population with SNP genotype “aa”.
Scenario 5 The coefficients βKelAa and βKelAA were set to 0.05βKel , and the other effect parameters
were set to 0.
Scenario 6 The coefficients βK12Aa and βK12AA were set to 0.30βK12 , and the other effect parameters
were set to 0.
Scenario 7 The coefficients βK21Aa and βK21AA were set to 0.50βK21 , and the other effect parameters
were set to 0.
In these scenarios, the random-effects distributions were set to “correctly specified” in NLMM. We
assumed that the random-effect vector γi is normally distributed with a mean vector 0 and a covariance
matrix diag(τ 2Vd, τ
2
K12
, τ 2K21), where the standard deviation for random effects was set to 0.12, 0.68, and
0.89, respectively.
Powers, biases, andMSEs of GEE (V̂s), GEE (V˜s), and NLMM are shown in Tables 3 and 4. Because
GEE (V̂s) and GEE (V˜s) differ only in variances, results of biases and MSEs were combined as GEE
(V̂s), GEE (V˜s) in Tables 3 and 4.
NLMM was the most powerful method. The power of the Wald-type test of GEE (V̂s) was about
0.021–0.295 smaller, and that of GEE (V˜s) was about 0.024–0.339 smaller, than that of NLMM (Table
3). The power of the asymptotic F -test of GEE (V̂s) was about 0.030–0.324 smaller, and that of GEE
(V˜s) was about 0.033–0.383 smaller, than that of NLMM (Table 3). Furthermore, because V̂s < V˜s, the
power of GEE (V̂s) was higher than that of GEE (V˜s) in all scenarios. Power increased with the sum of
subgroup sample size of naa + nAa or naa + nAA.
The biases and MSEs of GEE (V̂s, V˜s) were larger than those of NLMM, as shown in Tables 3 and
4. However, these results did not indicate a discernible trend.
Therefore, unless influenced by inflation of the type-I error rates, the power of NLMM might be
greater than those of GEE (V̂s) and GEE (V˜s).
4.3 Computation time and convergence proportion for iterative calculation
In this Section, we compare computation time and convergence proportion for iterative calculation of
GEE (V̂s), GEE (V˜s), and NLMM. All computations were performed on a personal computer with a
3.0-GHz Intel Core 2 Duo CPU and 3.25 GB of RAM running 32-bit Windows XP. Computation times
and convergence proportions for iterative calculations for each scenario are shown in Table 5.
GEE (V̂s) was the fastest method, GEE (V˜s) required 1.2–1.4-fold longer, and NLMM required
849.3–1630.3-fold longer than GEE (V̂s), as shown in Table 5. For instance, computational times of
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Table 3. Powers, biases, and MSEs of GEE (V̂s), GEE (V˜s), and NLMM for MAF = 0.25 in
Scenarios 4–7.
Scenario 4 Scenario 5 Scenario 6 Scenario 7
Parameter βVdAa βVdAA βKelAa βKelAA βK12Aa βK12AA βK21Aa βK21AA
Power
GEE (V̂s) 0.765
c0.272 0.897 c0.294 0.819 c0.186 0.086 0.069
GEE (V˜s) Wald 0.762
c0.246 0.894 c0.263 0.811 c0.142 0.075 0.047
NLMMa 0.786 0.418 0.957 0.484 0.919 0.481 0.152 0.100
GEE (V̂s)
c0.660 c0.757 c0.610 c0.072
GEE (V˜s) F
c0.638 c0.728 c0.551 c0.055
NLMMa 0.777 0.948 0.934 0.179
Bias
GEE (V̂s, V˜s)
b −0.040 −0.041 −0.001 −0.001 d0.021 d0.048 −0.014 d0.040
NLMMa −0.039 −0.037 −0.002 −0.002 −0.007 −0.016 −0.010 0.017
MSE
GEE (V̂s, V˜s)
b 0.010 0.017 <0.001 0.001 0.034 d0.129 0.042 0.164
NLMMa 0.010 0.016 <0.001 0.001 0.028 0.104 0.050 0.172
aValues of the NLMM have been calculated from simulations with a low convergence proportion for iterative
calculation (see Subsection 3.3).
bBecause GEE (V̂s) and GEE (V˜s) differ only in variances, results of biases were combined as GEE (V̂s, V˜s).
cValues for which there was more than a 0.1 inferior difference between GEE (V̂s), GEE (V˜s), and NLMM are
highlighted.
dValues for which there was more than a 0.01 inferior difference between GEE (V̂s, V˜s) and the NLMM are
highlighted.
The number of simulations was 1000.
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Table 4. Powers, biases, and MSEs of GEE (V̂s), GEE (V˜s), and NLMM for MAF = 0.50 in
Scenarios 4–7.
Scenario 4 Scenario 5 Scenario 6 Scenario 7
Parameter βVdAa βVdAA βKelAa βKelAA βK12Aa βK12AA βK21Aa βK21AA
Power
GEE (V̂s) 0.875 0.767 0.810
c0.687 c0.696 c0.548 0.065 0.061
GEE (V˜s) Wald 0.868 0.752 0.806
c0.665 c0.679 c0.532 0.055 0.054
NLMMa 0.918 0.815 0.889 0.805 0.845 0.738 0.150 0.126
GEE (V̂s) 0.914 0.860
c0.747 0.081
GEE (V˜s) F 0.911 0.848
c0.732 c0.066
NLMMa 0.944 0.934 0.903 0.177
Bias
GEE (V̂s, V˜s)
b 0.004 0.005 −0.001 −0.001 0.017 0.021 0.017 0.009
NLMMa 0.003 0.004 −0.001 <0.001 −0.011 −0.014 −0.008 −0.007
MSE
GEE (V̂s, V˜s)
b 0.004 0.005 0.001 0.001 0.042 0.059 0.056 0.075
NLMMa 0.003 0.004 0.001 0.001 0.034 0.049 0.060 0.080
aValues of the NLMM have been calculated from simulations with a low convergence proportion for iterative
calculation (see Subsection 3.3).
bBecause GEE (V̂s) and GEE (V˜s) differ only in variances, results of biases were combined as GEE (V̂s, V˜s).
cValues for which there was more than a 0.1 inferior difference between GEE (V̂s), GEE (V˜s), and NLMM are
highlighted.
The number of simulations was 1000.
GEE (V̂s), GEE (V˜s), and NLMM in Scenario 1 (MAF = 0.25), whose dataset includes 1000 SNPs,
were 8.7, 10.1, and 8050.8 minutes, respectively.
The convergence success of GEE (V̂s) and GEE (V˜s) was achieved perfectly in all scenarios. How-
ever, the convergence success of NLMM did not even reach 70%; NLMM tended not to converge for
data sets with relatively large random effects. In genome-wide PGx studies, oligonucleotide SNP arrays
can provide information about 100,000–4,300,000 SNPs. For instance, if the convergence success is
70% with 100,000 SNPs, we derived no information for 30,000 SNPs. Therefore, the simulation results
suggested that GEE (V̂s) and GEE (V˜s) perform at a relatively high speed with stable computation in
genome-wide settings.
5. Application to an actual genome-wide PGx study data
We determined GEE (V̂s) and GEE (V˜s) using a genome-wide PGx study [30], which analyzed plasma
concentrations of gemcitabine (n = 233 patients) with respect to 109,365 gene-centric SNPs using the
Sentrix Human-1 Genotyping BeadChip (Illumina Inc., San Diego, CA). For reducing false positives,
the P -value cutoff of asymptotic F -tests was set to α = 1.14 × 10−7 = 0.05/109365/4 as a simple
Bonferroni adjustment. The results showed that 82 SNPs were significant by GEE (V̂s), and 79 SNPs
were significant by GEE (V˜s). These computations of the 109,365 SNPs were finished in 16.3 hours for
GEE (V̂s) and 19.9 hours for GEE (V˜s).
Table 6 shows a result for a SNP (rs234630) chosen from among the 82 SNPs significant by GEE
(V̂s). Note that the tests for the null hypotheses indicated that a SNP does not affect PK parameters
(e.g., H0 : βVdAa = βVdAA = 0). Further, results of NLMM with a Gaussian random-effects vector
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Table 5. Computation time per 1000 SNPs, ratio of GEE (V̂s) computation time, and convergence
proportion for iterative calculations
MAF = 0.25 MAF = 0.50
Computation Computation
time per Ratio of Percent time per Ratio of Percent
1000 SNPs GEE (V̂s) convergence 1000 SNPs GEE (V̂s) convergence
(minutes) (minutes)
Scenario 1
GEE (V̂s) 8.7 1.0 100.0 4.9 1.0 100.0
GEE (V˜s) 10.1 1.2 100.0 6.5 1.3 100.0
NLMM 8050.8 928.7 65.0 7184.3 1459.0 61.6
Scenario 2
GEE (V̂s) 7.7 1.0 100.0 8.3 1.0 100.0
GEE (V˜s) 9.0 1.2 100.0 9.6 1.2 100.0
NLMM 6709.7 870.7 63.7 8066.3 977.1 66.5
Scenario 3
GEE (V̂s) 8.0 1.0 100.0 4.2 1.0 100.0
GEE (V˜s) 9.3 1.2 100.0 5.5 1.3 100.0
NLMM 6753.9 849.3 57.7 4679.5 1116.7 58.1
Scenario 4
GEE (V̂s) 7.6 1.0 100.0 4.2 1.0 100.0
GEE (V˜s) 8.9 1.2 100.0 5.8 1.4 100.0
NLMM 7807.9 1023.6 64.5 6804.6 1630.3 66.1
Scenario 5
GEE (V̂s) 4.7 1.0 100.0 7.2 1.0 100.0
GEE (V˜s) 5.9 1.3 100.0 8.6 1.2 100.0
NLMM 6169.9 1323.1 66.0 8128.7 1136.7 65.4
Scenario 6
GEE (V̂s) 7.5 1.0 100.0 7.6 1.0 100.0
GEE (V˜s) 9.2 1.2 100.0 8.9 1.2 100.0
NLMM 7779.4 1033.0 62.3 10864.2 1422.5 62.0
Scenario 7
GEE (V̂s) 8.4 1.0 100.0 7.9 1.0 100.0
GEE (V˜s) 10.3 1.2 100.0 9.7 1.2 100.0
NLMM 10988.9 1303.1 62.6 10168.4 1279.4 57.1
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Table 6. Comparison of SNP analyses using GEE (V̂s) and NLMM
Method Parameter Estimate S.E. d.f. P -value denom. d.f. P -value
(Wald) (Wald) (F ) (F )
GEE (V̂s) βVd 3.87 0.029 44.0 3.55×10−59 – –
βVdAa −0.03 0.057 24.4 5.69×10−01 3.0 2.35×10−01
βVdAA 0.18 0.085 2.5 1.40×10−01
βKel 1.31 0.017 44.4 1.34×10−48 – –
βKelAa −0.03 0.036 24.2 4.40×10−01 10.4 a6.74× 10−10
βKelAA −0.87 0.036 7.2 3.62×10−08
βK12 −2.30 0.066 16.2 1.27×10−16 – –
βK12Aa −0.10 0.124 41.6 4.42×10−01 24.0 a< 1.11× 10−16
βK12AA 2.85 0.079 17.2 1.15×10−17
βK21 −0.80 0.087 14.0 2.64×10−07 – –
βK21Aa 0.04 0.160 38.9 7.99×10−01 11.5 a1.15× 10−11
βK21AA −4.73 0.157 7.4 4.69×10−09
NLMM βVd 3.71 0.036 231.0 6.74×10−194 – –
βVdAa – – – – – –
βVdAA 0.33 0.089 231.0 2.83×10−04 231.0 2.83×10−04
βKel 1.39 0.022 231.0 8.42×10−149 – –
βKelAa – – – – – –
βKelAA −0.37 0.097 231.0 1.98×10−04 231.0 1.98×10−04
βK12 −2.12 0.085 231.0 4.02×10−67 – –
βK12Aa – – – – – –
βK12AA 1.40 0.431 231.0 1.32×10−03 231.0 1.32×10−03
βK21 −0.52 0.071 231.0 2.85×10−12 – –
βK21Aa – – – – – –
βK21AA −3.72 0.532 231.0 2.80×10−11 231.0 a2.80× 10−11
aValues that the coefficients of a SNP effects were smaller than the significance level α = 1.14 × 10−7 are
highlighted.
Abbreviations: S.E. = standard error, d.f. = degrees of freedom, denom. = denominator.
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γ i ∼ N(0, diag(τ 2K12 , τ 2K21)) after variable selection are also summarized in Table 6, because NLMMwith
a Gaussian random-effects vector γi ∼ N(0, diag(τ 2Vd , τ 2K12, τ 2K21)) failed to converge. The convergence
success of NLMM without variable selection was 54.9 % (45 SNPs) among the 82 SNPs. Computations
for NLMM of the 82 SNPs were finished in 24.1 hours.
According to the results obtained based on GEE (V̂s), the coefficients of the SNP effects, (βKelAa, βKelAA),
(βK12Aa, βK12AA), and (βK21Aa, βK21AA) were statistically significant at α. In contrast, NLMM-based re-
sults indicated that only the coefficients (βK21Aa, βK21AA) were statistically significant. As a result, both
GEE (V̂s) and NLMM indicated that the SNP affected PK parameter K21 of gemcitabine.
In addition, we conducted similar analyses for all 82 significant SNPs, and observed that 74 of them
(90.2%) were statistically significant at α by both GEE (V̂s) and NLMM.
Therefore, we consider that GEE (V̂s) is a suitable alternative method for analyzing population PK
data in genome-wide PGx studies.
6. Discussion
NLMM, which accounts for inter-individual variability in PK parameters, is a useful method for analyz-
ing a genetic polymorphism in relation to population PK data [7, 8, 9, 10, 11]. However, when applying
an NLMM to large-scale data, three problems occur in association with an assumption of random effects:
(i) computation time [8]; (ii) convergence of iterative calculation [16, 17]; and (iii) random-effects mis-
specification [18]. In fact, the results of simulations show that NLMM was the slowest and the most
computationally unstable; furthermore, the type-I error rate of NLMM was inflated in some cases of
random-effects misspecification. As an alternative effective approach to resolving these issues, in this
article we proposed valid inference methods for using GEE even under inter-individual variability, and
provided theoretical justifications of the proposed GEE estimators for population PK data. The proposed
GEE methods applied a potentially misspecified model [24, 25] to account for inter-individual variabil-
ity in PK parameters. The proposed GEE estimator, β̂, can be interpreted as the population-weighted
average of the individual parameter vector, βi, under the true model. The effectiveness of the proposed
method was demonstrated through simulations and an application to a genome-wide PGx study [30] on
gemcitabine, a nucleoside anticancer drug. As such, the proposed GEE methods would provide efficient
and robust alternatives for analyzing population PK data in genome-wide PGx studies.
From the simulation results, the type-I error rates of GEE (V̂s) were well controlled below the nom-
inal level in all conditions, and were closer to the nominal level than the type-I error rates of GEE (V˜s)
despite the downward bias of V̂s. By contrast, in some instances, the type-I error rate of NLMM was
inflated; consequently, GEE (V̂s) might be more robust than NLMM under various structures of individ-
ual variations. Therefore, the results of this study show that GEE (V̂s) yields valid inference even under
inter-individual variability, without assumptions of a random-effects distribution.
In all simulations, GEE (V̂s) was computationally fastest and most stable. In particular, the possible
impact of the convergence failures on the type-I error rate and power of NLMMwas not clear, and should
not be ignored. Thus, GEE (V̂s) is more efficient and computationally stable than NLMM.
In the application to the genome-wide PGx study, GEE (V̂s) gave results for all 109,365 SNPs in a
relatively short time. By contrast, a complex NLMM failed to converge and required variable selection.
As the result of additional analyses, many of the significant SNPs detected by GEE (V̂s) can also be
detected by NLMM. Therefore, GEE (V̂s) can be applied to genome-wide PGx studies, and is remarkably
stable and convenient.
The proposed approach may be applicable to other situations. Because it was formulated based on
GEE, it can deal with correlated response data. Furthermore, it treats inter-individual variability in PK
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parameters by a potentially misspecified model. Therefore, it may be applied to correlated response
data with inter-individual variability in model parameters. In particular, when problems occur in asso-
ciation with a strong assumption of random effects, in many cases the proposed approach represents an
alternative to mixed models. However, further research is needed to determine whether this approach is
applicable to other settings, because the properties of β∗ and the performance of the proposed tests are
not clear in every particular case.
In summary, this study has demonstrated that GEE (V̂s) yields a valid inference even under inter-
individual variability, and is more efficient and computationally stable than NLMM. We conclude that
GEE (V̂s) represents an alternative approach for analyzing population PK data in genome-wide PGx
studies.
APPENDIX A. An evaluation of β∗
We present a derivation for the properties of a constant β∗ listed in Section 3.3 Theorem 1.
Using a first-order Taylor expansion of the expectation of equation (2) around β∗ = βi, we get
E
[
K∑
i=1
Ui(Yi;β∗)
]
≈
K∑
i=1
{
E [Ui(Yi;βi)] + E
[
∂Ui(Yi;β∗)
∂βT∗
∣∣∣∣
β
∗
=βi
]
(β∗ − βi)
}
.
Here E [Ui(Yi;βi)] = 0 and E[∂Ui(Yi;β∗)/∂β
T
∗ |β∗=βi] = I0i(βi). Because by definition
E [Ui(Yi;β∗)] = 0,
we arrive at
K∑
i=1
I0i(βi)(β∗ − βi) ≈ E
[
K∑
i=1
Ui(Yi;β∗)
]
= 0.
Hence,
β∗ ≈
{
K∑
i=1
I0i(βi)
}−1{ K∑
i=1
I0i(βi)βi
}
.
APPENDIX B. A asymptotic evaluation of d̂
We present a derivation of the d.f. d and the estimator d̂ listed in Section 3.6.
We applied the moment estimator of the d.f. from Fay and Graubard [37]. Assuming UT =
(U1(Y1;β), U2(Y2;β), . . ., UK(YK ;β))
T is normally distributed with mean vector 0 and covariance
matrix Ψ, where Ψ = block-diag(Ψ1,Ψ2, . . . ,ΨK) is a block-diagonal matrix. The d.f. can be shown
to be d = {trace(ΨM)}2/trace(ΨMΨM), where M = block-diag(M1,M2, . . . ,MK) is a block-
diagonal matrix, andMi is defined as follows. Rewrite c
TV̂sc as
cTV̂sc = K
−1
K∑
i=1
{Ui(Yi; β̂)}TMi{Ui(Yi; β̂)},
where Mi = D̂
T
i V̂
−1
i D̂icc
TD̂iV̂
−1
i D̂
T
i . Under these assumptions, d(U
TMU)/cTVsc is asymptoti-
cally distributed as a chi-square random variable with d.f. d. That is, E[UTMU] = cTVsc and
Var[d(UTMU)/cTVsc] = d
2Var[UTMU](cTVsc)
−2 = 2d. Solving these systems of equations,
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d = 2{E[UTMU]}2/Var[UTMU]. Furthermore, E[UTMU] = trace(ΨM) and Var[UTMU] =
2trace(ΨMΨM) [49], becauseUTMU is a quadratic form. SinceΨi can estimate by
Ψ̂i = D̂
T
i V̂
−1
i ŜiŜ
T
i V̂
−1
i D̂i,
the estimator is given by d̂ = {trace(Ψ̂M)}2/trace(Ψ̂MΨ̂M).
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